Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fresenius SE & Co. KGaA

http://www.fresenius.com

Latest From Fresenius SE & Co. KGaA

Leaner Kabi Drives Higher Savings Goal For Fresenius, China ‘Soft’ In 2024

Fresenius Kabi insists there is a “business plan behind everything” as it divulged a higher cost savings goal for the end of next year, following a fruitful 2023. But queries over margins led the company to stress that it was combatting a variety of uncertainties, especially in China and for its burgeoning biosimilars unit.

Sales & Earnings Strategy

AbbVie Stays On Script With Michael As Next CEO

As previously indicated, AbbVie will go with an internal candidate, president and COO Robert Michael, to succeed Richard Gonzalez as CEO. The company has recently positioned Michael prominently.

Executive Changes Leadership

Nine Pivotal Studies To Look Out For In 2024

While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.

Clinical Trials Commercial

AbbVie’s Gonzalez Outlines CEO Succession Process

AbbVie may look to an internal successor to Rick Gonzalez once he is satisfied the company is back on a growth trajectory. Skyrizi and Rinvoq continue meteoric growth, with increased sales projections.

Sales & Earnings Business Strategies
See All

Company Information

  • Industry
  • Distributors
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
  • Services
  • Other Names / Subsidiaries
    • APP Pharmaceuticals, Inc.
    • Asia Renal Care Ltd.
    • Fresenius Kabi Pharmaceuticals Holding, Inc.
    • Fresenius Medical Care
    • Fresenius Medical Group AG
    • Vifor-Fresenius Medical Care Renal Pharma Ltd. (VFMCRP)
    • Xenios AG
UsernamePublicRestriction

Register